A questionnaire (Migraine Questionnaire; MQ) was developed to help pharmacists identify consumers with migraine suitable for non-prescription treatment with a triptan. Adults, who knew or thought that they had migraine, participated in three, sequential, community-based studies to validate the MQ. Overall, 1,353 subjects completed independent assessments with a pharmacist and a clinician (reference standard). The accuracy of the pharmacist assessment of suitability for a triptan was compared with the clinician assessment. Clinicians using their standard practice determined that triptan therapy was suitable in 76.8% of cases compared with 48.8% for pharmacists using the MQ. The lack of concordance between pharmacists and clinicians in the false-positive cases (n = 113 of 660 subjects considered suitable for triptan by the pharmacists) usually related to headache diagnosis (57.5%), not safety aspects. The MQ is an effective tool for pharmacists to guide appropriate recommendation of a non-prescription triptan for migraine. © The Author(s) 2008.
CITATION STYLE
Diener, C. C., Dowson, A., Whicker, S., & Bacon, T. (2008). Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan. Journal of Headache and Pain, 9(6), 359–365. https://doi.org/10.1007/s10194-008-0070-6
Mendeley helps you to discover research relevant for your work.